Benitec Biopharma, Inc. (BNTC)
11.50
+0.12
(+1.05%)
USD |
NASDAQ |
Dec 19, 16:00
11.50
0.00 (0.00%)
After-Hours: 17:10
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 389.42M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -3.89% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 4.161 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0087 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.67% |
Profile
| Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA. |
| URL | http://www.benitec.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 12, 2026 (est.) |
| Last Earnings Release | Nov. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 01, 2018 |
Ratings
Profile
| Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA. |
| URL | http://www.benitec.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 12, 2026 (est.) |
| Last Earnings Release | Nov. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 01, 2018 |